PIK3CA and neoplasm: CTG-1260 tumors harbor both an ESR1D538G mutation and mutations in PIK3CA and PTEN, and were resistant to fulvestrant in vivo and both single and combination RMC-6272 treatment significantly reduced tumor growth.